Entecavir · Baraclude, ETV

What is Entecavir?

Entecavir is a deoxyguanosine nucleoside analogue that is phosphorylated to its triphosphate form, which competes with deoxyguanosine triphosphate and inhibits the hepatitis B virus reverse transcriptase. It is used in the treatment of chronic hepatitis B virus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Baraclude, ETV, BMS-200475-01, SQ-34676

Drug type

Small molecule

Targets

hepatitis B virus reverse transcriptase

Mechanism

Inhibitor of hepatitis B virus reverse transcriptase

Pathways

HBV reverse transcription, HBV DNA synthesis

Therapy area

Infectious disease

Developer

Bristol Myers Squibb

In trials of

ASMB

FDA status

Approved as Baraclude (March 29, 2005), NDA021797 · FDA label

UNII

5968Y6H45M

✅ FDA-approved uses

• Chronic hepatitis B virus infection

From the indications section of the FDA label (version of Nov 6, 2019). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis B

Sources

• FDA label (DailyMed)
• FDA label Baraclude (2019-11-06), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT04781647

Updated Oct 11, 2026.